The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity

Christina K. Baumgartner, Hakimeh Ebrahimi-Nik, Arvin Iracheta-Vellve, Keith M. Hamel, Kira E. Olander, Thomas G. R. Davis, Kathleen A. McGuire, Geoff T. Halvorsen, Omar I. Avila, Chirag H. Patel, Sarah Y. Kim, Ashwin V. Kammula, Audrey J. Muscato, Kyle Halliwill, Prasanthi Geda, Kelly L. Klinge, Zhaoming Xiong, Ryan Duggan, Liang Mu, Mitchell D. Yeary, James C. Patti, Tyler M. Balon, Rebecca Mathew, Carey Backus, Domenick E. Kennedy, Angeline Chen, Kenton Longenecker, Joseph T. Klahn, Cara L. Hrusch, Navasona Krishnan, Charles W. Hutchins, Jax P. Dunning, Marinka Bulic, Payal Tiwari, Kayla J. Colvin, Cun Lan Chuong, Ian C. Kohnle, Matthew G. Rees, Andrew Boghossian, Melissa Ronan, Jennifer A. Roth, Meng-Ju Wu, Juliette S. M. T. Suermondt, Nelson H. Knudsen, Collins K. Cheruiyot, Debattama R. Sen, Gabriel K. Griffin, Todd R. Golub, Nabeel El-Bardeesy, Joshua H. Decker, Yi Yang, Magali Guffroy, Stacey Fossey, Patricia Trusk, Im-Meng Sun, Yue Liu, Wei Qiu, Qi Sun, Marcia N. Paddock, Elliot P. Farney, Mark A. Matulenko, Clay Beauregard, Jennifer M. Frost, Kathleen B. Yates, Philip R. Kym, Robert T. Manguso